(firstQuint)Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer.

 To determine the response rate by RECIST criteria.

 To determine the progression free survival.

 To determine the median survival and overall survival at one year.

.

 Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer@highlight

To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.

